Bgm Group LtdBgm Group Ltd
Bgm Group Ltd

Bgm Group Ltd

BGM
Health Care·Pharmaceuticals

BGM Group Ltd. is a holding company, which engages in the technology fields of AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals. It operates through the following segments: Oxytetracycline and Licorice Products, and Traditional Chinese Medicine Derivatives (TCMD); Heparin Products and Sausage Casing; and Fertilizer. The Oxytetracycline and Licorice Products, and TCMD segment focuses on the development, manufacture, marketing, and sale of oxytetracycline products, licorice products, and TCMD. The Heparin Products and Sausage Casing segment treats cardiovascular diseases, cerebrovascular diseases, and hemodialysis. The Fertilizer segment includes Xiongguan, Organic Fertilizer and Xiongguan, and Organic-Inorganic Compound Fertilizer. The company was founded on February 7, 2019 and is headquartered in Chengdu, China.

China
Market cap
No dataNo data
Revenue
$37.9M+51.1% YoY
Net income
$-19.9M−1282.1% YoY
Free cash flow
$-3.9M−1395.3% YoY

Market

Listed stock
BGMPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
$37.9M+51.1% YoY
Operating income
$-12.6M−2131.7% YoY
Net income
$-19.9M−1282.1% YoY
Free cash flow
$-3.9M−1395.3% YoY

Revenue, profit & cash trend

Revenue
Operating income
Net income
Free cash flow
Reference
Revenue: 2021 $57.1M, 2022 $64.9M, 2023 $46.5M, 2024 $25.1M, 2025 $37.9M. Operating income: 2021 $2.4M, 2022 $2.1M, 2023 $-2.6M, 2024 $-563.8K, 2025 $-12.6M. Net income: 2021 $3.1M, 2022 $1.1M, 2023 $-7.8M, 2024 $-1.4M, 2025 $-19.9M. Free cash flow: 2021 $-3.1M, 2022 $9.4M, 2023 $132.5K, 2024 $304.1K, 2025 $-3.9M. Reference line: Reference at $0.

Growth & profitability

Revenue growth
51.1%+9708 bps YoY
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-09-30 $2.4M, 2022-09-30 $2.1M, 2023-09-30 $-2.6M, 2024-09-30 $-563.8K, 2025-09-30 $-12.6M. Net income: 2021-09-30 $3.1M, 2022-09-30 $1.1M, 2023-09-30 $-7.8M, 2024-09-30 $-1.4M, 2025-09-30 $-19.9M. Free cash flow: 2021-09-30 $-3.1M, 2022-09-30 $9.4M, 2023-09-30 $132.5K, 2024-09-30 $304.1K, 2025-09-30 $-3.9M

Growth heatmap

2022202320242025CAGR
Revenue
+13.6%
-28.3%
-46.0%
+51.1%
-9.7%
Gross profit
+10.4%
-71.9%
+134.9%
+53.4%
+2.9%
Operating income
-12.0%
-224.2%
+78.4%
-2131.7%
No data
Free cash flow
+399.4%
-98.6%
+129.6%
-1395.3%
No data

Earnings quality

Operating cash flow
$-2.4M−535.9% YoY
Net income
$-19.9M−1282.1% YoY
Free cash flow
$-3.9M−1395.3% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-09-30 12%, 2024-09-30 -38%, 2023-09-30 -4%, 2022-09-30 1175%, 2021-09-30 11%. Free cash flow: 2025-09-30 20%, 2024-09-30 -21%, 2023-09-30 -2%, 2022-09-30 875%, 2021-09-30 -101%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data